Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy

BACKGROUND: In Phase 3 studies of ustekinumab, a fully human monoclonal IL‐12/23p40 antibody approved for moderate‐to‐severe Crohn's disease, patients entered a long‐term extension after completing 8 weeks of induction and 44 weeks of maintenance treatment. Efficacy through 92 weeks and safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandborn, W. J., Rutgeerts, P., Gasink, C., Jacobstein, D., Zou, B., Johanns, J., Sands, B. E., Hanauer, S. B., Targan, S., Ghosh, S., de Villiers, W. J. S., Colombel, J.‐F., Feagan, B. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Ustekinumab for Crohn's Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032827/
https://www.ncbi.nlm.nih.gov/pubmed/29797519
http://dx.doi.org/10.1111/apt.14794

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032827/
https://www.ncbi.nlm.nih.gov/pubmed/29797519
http://dx.doi.org/10.1111/apt.14794

Ejemplares similares